Oculis FY26 H1 net loss narrows to CHF 38.82 million
OCS•Pipeline progress
PIONEER-1 Privosegtor site activations advanced; FDA feedback cleared no added preclinical work for the acute MS relapse IND, targeted for Q4 2026.
First-half results and cash position
Oculis posted a net loss of CHF 38.82 million for the six months ended June 30, narrowing from CHF 58.59 million a year earlier.
- Operating loss widened to CHF 45.3 million from CHF 40.74 million, while finance result swung to CHF 6.38 million from a loss of CHF 17.86 million.
- R&D expenses edged up to CHF 29.33 million from CHF 29.68 million; G&A costs rose to CHF 16.49 million from CHF 11.61 million.
- Cash, cash equivalents and short-term investments totaled $282.3 million at June 30, supporting runway into 2H 2029.
